RxDoctor Payments Data

George Lin, MD

Family Medicine · Hacienda Heights, CANPI 1679676035

Payments from drug & device makers

$28,799in general payments, 2019–2025

Across 944 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Gilead$5K
  • Amgen$3K
  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • GSK$2K
  • plus $9K from 34 others

What the payments were for

  • Consulting fees$1,9007%
  • Travel & lodging$5792%
  • Food & beverage$26,24291%
  • Education$780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,799 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$370,036
Medicare patients
138
Services billed
25,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$179,299
ProliaDenosumab41$66,543
Synjardy XrEmpagliflozin/Metformin Hcl31$52,589
JardianceEmpagliflozin43$45,440
MounjaroTirzepatide29$43,652
KerendiaFinerenone46$42,749
RybelsusSemaglutide17$30,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,979
XareltoRivaroxaban17$25,825
FarxigaDapagliflozin Propanediol20$24,805
Nurtec OdtRimegepant Sulfate12$23,507
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$15,890
Atorvastatin Calcium910$11,552
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$8,581
Metformin Hcl ErMetformin Hcl382$6,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,560$209,412150 claims
Boehringer IngelheimSynjardy Xr, Jardiance$1,368$98,02974 claims
AmgenProlia$3,001$66,54341 claims
Lilly USA, LLCMounjaro$2,042$43,65229 claims
BayerKerendia$334$42,74946 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$5,043$27,82231 claims
GSKTrelegy Ellipta$1,943$26,97918 claims
Johnson & JohnsonXarelto$1,627$25,82517 claims
PfizerNurtec Odt$569$23,50712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Hacienda Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →